OncoCyte Statistics
Total Valuation
OncoCyte has a market cap or net worth of $96.95 million. The enterprise value is $91.98 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoCyte has 28.60 million shares outstanding. The number of shares has increased by 70.84% in one year.
| Current Share Class | 28.60M |
| Shares Outstanding | 28.60M |
| Shares Change (YoY) | +70.84% |
| Shares Change (QoQ) | +26.75% |
| Owned by Insiders (%) | 13.42% |
| Owned by Institutions (%) | 7.66% |
| Float | 10.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.56 |
| Forward PS | 119.65 |
| PB Ratio | -7.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62
| Current Ratio | 1.62 |
| Quick Ratio | 1.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | -276.75 |
Financial Efficiency
Return on equity (ROE) is -910.86% and return on invested capital (ROIC) is -146.37%.
| Return on Equity (ROE) | -910.86% |
| Return on Assets (ROA) | -26.42% |
| Return on Invested Capital (ROIC) | -146.37% |
| Return on Capital Employed (ROCE) | -83.60% |
| Revenue Per Employee | $38,388 |
| Profits Per Employee | -$1.24M |
| Employee Count | 49 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.16% in the last 52 weeks. The beta is 0.98, so OncoCyte's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +31.16% |
| 50-Day Moving Average | 3.08 |
| 200-Day Moving Average | 2.85 |
| Relative Strength Index (RSI) | 63.03 |
| Average Volume (20 Days) | 46,348 |
Short Selling Information
The latest short interest is 365,089, so 1.28% of the outstanding shares have been sold short.
| Short Interest | 365,089 |
| Short Previous Month | 373,800 |
| Short % of Shares Out | 1.28% |
| Short % of Float | 3.50% |
| Short Ratio (days to cover) | 3.22 |
Income Statement
In the last 12 months, OncoCyte had revenue of $1.88 million and -$60.93 million in losses. Loss per share was -$4.66.
| Revenue | 1.88M |
| Gross Profit | 828,000 |
| Operating Income | -23.25M |
| Pretax Income | -36.35M |
| Net Income | -60.93M |
| EBITDA | -21.68M |
| EBIT | -23.25M |
| Loss Per Share | -$4.66 |
Full Income StatementBalance Sheet
The company has $8.64 million in cash and $3.66 million in debt, giving a net cash position of $4.97 million or $0.17 per share.
| Cash & Cash Equivalents | 8.64M |
| Total Debt | 3.66M |
| Net Cash | 4.97M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | -12.27M |
| Book Value Per Share | -0.70 |
| Working Capital | 4.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.71 million and capital expenditures -$516,000, giving a free cash flow of -$21.23 million.
| Operating Cash Flow | -20.71M |
| Capital Expenditures | -516,000 |
| Free Cash Flow | -21.23M |
| FCF Per Share | -$0.74 |
Full Cash Flow StatementMargins
| Gross Margin | 44.02% |
| Operating Margin | -1,235.89% |
| Pretax Margin | -3,225.04% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -70.84% |
| Shareholder Yield | -70.84% |
| Earnings Yield | -62.84% |
| FCF Yield | -21.90% |
Analyst Forecast
The average price target for OncoCyte is $4.42, which is 30.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.42 |
| Price Target Difference | 30.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jul 25, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
OncoCyte has an Altman Z-Score of -15.51 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.51 |
| Piotroski F-Score | 4 |